Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
UCB PHARMA SA
🇧🇪
Belgium
Country
🇧🇪
Belgium
Ownership
Public, Subsidiary
Established
1928-01-01
Employees
9K
Market Cap
$34.9B
Website
https://www.ucb-iberia.com/home
Clinical Trials
Related News
A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy
Phase 3
Completed
Conditions
Painful Diabetic Neuropathy
Interventions
Drug: Placebo
Drug: SPM 929
Subscribe
First Posted Date
2006-07-10
Last Posted Date
2024-03-22
Lead Sponsor
UCB Pharma
Target Recruit Count
551
Registration Number
NCT00350103
Subscribe
Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes
Phase 1
Completed
Conditions
Narcolepsy With Cataplexy
Interventions
Drug: Sodium Oxybate (Xyrem)
Subscribe
First Posted Date
2006-06-29
Last Posted Date
2022-04-08
Lead Sponsor
UCB Pharma SA
Target Recruit Count
25
Registration Number
NCT00345800
Subscribe
UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)
Completed
Conditions
Pregnancy Complications
Seizures
Birth Defects
Epilepsy
Subscribe
First Posted Date
2006-06-28
Last Posted Date
2016-09-02
Lead Sponsor
UCB Pharma
Target Recruit Count
516
Registration Number
NCT00345475
Locations
🇺🇸
INC Research, Wilmington, North Carolina, United States
Subscribe
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
Phase 3
Completed
Conditions
Crohn's Disease
Interventions
Biological: Certolizumab pegol (CDP870)
Subscribe
First Posted Date
2006-06-06
Last Posted Date
2018-08-07
Lead Sponsor
UCB Pharma
Target Recruit Count
233
Registration Number
NCT00333788
Subscribe
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
Phase 2
Completed
Conditions
Crohn's Disease
Interventions
Biological: Certolizumab pegol
Subscribe
First Posted Date
2006-05-24
Last Posted Date
2015-03-18
Lead Sponsor
UCB Pharma
Target Recruit Count
46
Registration Number
NCT00329420
Subscribe
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: Certolizumab Pegol (Cimzia®)
Subscribe
First Posted Date
2006-05-24
Last Posted Date
2019-05-06
Lead Sponsor
UCB Pharma
Target Recruit Count
71
Registration Number
NCT00329303
Subscribe
Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam
Completed
Conditions
Epilepsy
Subscribe
First Posted Date
2006-04-27
Last Posted Date
2012-05-25
Lead Sponsor
UCB Pharma
Target Recruit Count
600
Registration Number
NCT00319605
Subscribe
Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen
Phase 3
Completed
Conditions
Rhinitis, Allergic, Seasonal
Subscribe
First Posted Date
2006-04-18
Last Posted Date
2013-12-16
Lead Sponsor
UCB Pharma
Target Recruit Count
403
Registration Number
NCT00315523
Subscribe
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
Phase 3
Completed
Conditions
Crohn's Disease
Interventions
Biological: Certolizumab pegol
Other: Placebo
Subscribe
First Posted Date
2006-03-29
Last Posted Date
2018-08-07
Lead Sponsor
UCB Pharma
Target Recruit Count
539
Registration Number
NCT00308581
Subscribe
Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab
Phase 3
Terminated
Conditions
Crohn's Disease
Interventions
Biological: Certolizumab pegol
Subscribe
First Posted Date
2006-03-28
Last Posted Date
2011-08-31
Lead Sponsor
UCB Pharma
Target Recruit Count
16
Registration Number
NCT00307931
Subscribe
Prev
1
17
18
19
20
21
27
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy